Actively Recruiting
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Led by Peking Union Medical College Hospital · Updated on 2024-07-10
9
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will undergo radioligand therapy (RLT). All patients underwent 68Ga-PSMA and 18F-FDG PET/CT for selection and were randomly divided into three groups of 3 people each.The three groups received an approximately 1.11 GBq (30mCi), 1.85 GBq (50 mCi) and 2.59 GBq (70mCi) of 177Lu-PSMA-EB-01 up to 2 cycles, respectively.
CONDITIONS
Official Title
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Progressive metastatic castration-resistant prostate cancer
- Tumors with high PSMA expression confirmed on 68Ga-PSMA PET/CT
You will not qualify if you...
- Serum creatinine level greater than 150 µmol per liter
- Hemoglobin level less than 10.0 g/dl
- White-cell count less than 4.0×10⁹/L
- Platelet count less than 100×10⁹/L
- Total bilirubin level more than 3 times the upper limit of normal
- Serum albumin level more than 3.0 g per deciliter
- Cardiac insufficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD
CONTACT
G
Guochang Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here